In this retrospective study, we determined the prevalence of PPM1D gene mutations in r/r DLBCL patients and analyzed the impact of PPM1D mutations on the safety and efficacy of CD19-targeted CAR T-cell therapy. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.